Entity

Time filter

Source Type


Grant
Agency: Cordis | Branch: FP7 | Program: CSA-SA | Phase: INCO.2012-2.2 | Award Amount: 855.37K | Year: 2012

The EU and Morocco are fully engaged in a strong and deepen cooperation supported by a high level policy dialogue, and pertaining to multiple sectors including research and innovation. At the institutional level, the Association agreement (1996), the S&T agreement (2003), the European neighboring policy (2004), The new advanced status and the program called To succeed the advanced status has put emphasis on the consolidation of scientific and technological ties, and are supported by relevant implementation mechanisms and instruments. In May 2011, an institutional twinning program is launched to strengthen and bring closer the Moroccan research and innovation system to ERA. Morocco is highly devoted to reinforce and intensify the current bilateral initiatives and programs in the field of science and technology, aiming to the preparation and definition of joint activities targeting thematics of mutual interest, to improve oriented industry based on S&T cooperation between EU and Morocco, to set up joint collaboration and networking of technical platforms and research laboratories.


J-AGE, the Coordination Action for the early implementation of the Joint Programming Initiative (JPI) More Years Better Lives the Challenges and Opportunities of Demographic Change, will support and foster the overall management of the JPI, the development of the Strategic Research Agenda and its implementation through joint activities between Member States, the mapping of relevant national programmes and a complementary foresight activity. Furthermore, the work plan will include dissemination and information exchange with scientific and societal stakeholders, policy makers and research funders as well as an evaluation and monitoring exercise. Ultimately, the project and the JPI seek to strengthen the base of multi-disciplinary and holistic ageing research in Europe and to provide scientific evidence for policy responses to demographic change.


J-AGEII, the Coordination Action for implementation and alignment activities of the Joint Programming Initiative (JPI) More Years Better Lives the Challenges and Opportunities of Demographic Change, will support and foster the overall management of the JPI, update the Strategic Research Agenda and support implementation through joint activities between Member States. Furthermore, the work plan will include dissemination and information exchange with scientific and societal stakeholders, policy makers and research funders as well as an evaluation and monitoring exercise. Ultimately, the project and the JPI seek to stimulate the alignment of relevant national programmes and EU initiatives, strengthen the base of multi-disciplinary and holistic ageing research in Europe and to provide scientific evidence for policy responses to demographic change.


Grant
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: INSO-7-2014 | Award Amount: 3.20M | Year: 2015

Building on the ERA-LEARN, NETWATCH & JPIs To Co Work predecessor projects ERA-LEARN 2020 will provide an integrated framework to make P2P more efficient and effective and support national and regional funding organisations in the preparation, implementation and monitoring of joint actions. ERA-LEARN 2020 will increase mutual learning within the P2P community and will thereby support the implementation of streamlined mechanisms. Useful input will be provided towards the analysis and possible future development of P2P formats. ERA-LEARN 2020 will highlight synergies between different forms of national/regional programme coordination and facilitate high-level analysis of P2P policy-related issues. It will provide tools for analysis and communication formats for supporting future developments of transnational programme coordination. The ERA-LEARN 2020 team is highly qualified & complementary with national authorities and experts for analysis with many years experience of P2P at both the operational and policy levels. ERA-LEARN 2020 will: 1. provide a web-based information, learning and support platform for P2P to avoid duplication of efforts; 2. support the ongoing optimisation of P2P networks by providing a toolbox for the wider activities of joint programming, particularly the JPIs, Art.185 and ERA-NET Cofund instrument, as well as their associated impacts; 3. implement a systematic process for monitoring & impact assessment of P2P networks, including their impacts at both the policy, programme and co-funded RTD project-level; 4. assess and benchmark current approaches to alignment and explore options for new modalities to better align national and/or regional activities under common research agendas; 5. implement an annual cycle of knowledge exchange aimed at increasing the impact of investment in P2P activities and exploring options to support less research intensive countries.


Grant
Agency: Cordis | Branch: H2020 | Program: CSA | Phase: NMP-09-2014 | Award Amount: 2.00M | Year: 2015

ENATRANS main objective is to network and support SMEs in translation of nanomedicine in Europe by providing a one-stop-shop service to interact and share information, experience and advice with up-to-date information and interactive tools, but also enabling personal contacts. To be successful SMEs need to understand the requirements of the complex ecosystem made up of regulatory and reimbursement agencies, as well as the requirements of large industrial companies and clinical needs. ENATRANS will gather and provide information about approval processes, regulatory authorities and agencies, clinical and market data, and specific nanomedicine value chain analysis, relevant SME support projects and organisations. ENATRANS will convert this critical information in dedicated learning programs and tools dedicated to translation of nanomedicine. ENATRANS aims at implementing the concept of a Translation Advisory Board (TAB) as central element of the ETPN White Paper. A TAB will be set-up with senior experienced translation experts to guide R&D teams (in SMEs and research institutes) along the translation process to successfully make it to clinical trials and later to the market. Promising projects identified and supported by the TAB need access to clinical centers for first studies in patients, which are able to handle the specificity of new nanotechnology based therapeutics. In addition, financial resources are needed to go pass the regulatory and scale-up processes, which often require funding from investors and/or large companies. ENATRANS will build bridges to clinical trial centers, investors and large companies. Promising projects need guidance to successfully master privileged contacts with the medical, the business or the investment community. ENATRANS will deliver special coaching sessions prior to showcasing of promising projects. Partners in ENATRANS are VDI/VDE-IT, Nanobiotix, CEA, bioanalytik-muenster, Tel Aviv University, Fondazione Don Gnocchi, TecMinho.

Discover hidden collaborations